181 related articles for article (PubMed ID: 8840740)
1. Update on MS treatment.
Ryan M
J Am Pharm Assoc (Wash); 1996 Jul; NS36(7):419-20. PubMed ID: 8840740
[No Abstract] [Full Text] [Related]
2. [Multiple sclerosis].
Itoyama Y
No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536
[No Abstract] [Full Text] [Related]
3. New treatments for multiple sclerosis.
Hutchinson M
Ir Med J; 1996; 89(2):44. PubMed ID: 8682623
[No Abstract] [Full Text] [Related]
4. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
5. Biogen wins Euro MS approval, but loses patents.
Brower V
Nat Biotechnol; 1997 May; 15(5):410. PubMed ID: 9131611
[No Abstract] [Full Text] [Related]
6. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
Pöllmann W; Erasmus LP; Feneberg W; Straube A
Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
[TBL] [Abstract][Full Text] [Related]
7. The future looks bright.
Wende KE
Rehab Manag; 1999; 12(2):32-4. PubMed ID: 10350900
[No Abstract] [Full Text] [Related]
8. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
9. [Clinical surveillance of patients with multiple sclerosis].
Cazzato G; Zorzon M
Recenti Prog Med; 2003 Apr; 94(4):173-6. PubMed ID: 12677789
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostics and drug therapy of multiple sclerosis].
Suomen Neurologinen Yhdistys ry
Duodecim; 2002; 118(13):1411-23. PubMed ID: 12239889
[No Abstract] [Full Text] [Related]
11. Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis.
Prescrire Int; 2009 Dec; 18(104):252. PubMed ID: 20025092
[No Abstract] [Full Text] [Related]
12. Disease-modifying drugs for the early treatment of multiple sclerosis.
Flachenecker P
Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
[TBL] [Abstract][Full Text] [Related]
13. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
[TBL] [Abstract][Full Text] [Related]
14. Seeing injectable ms therapies differently: they are more similar than different.
Johnson KP; Fox RJ; Arnold DL
Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129
[No Abstract] [Full Text] [Related]
15. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
Pula JH; Javed A
Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177
[TBL] [Abstract][Full Text] [Related]
16. [Emerging new therapies for relapsing remitting multiple sclerosis].
Anis S; Achiron A
Harefuah; 2014 Nov; 153(11):658-62, 687, 686. PubMed ID: 25563027
[TBL] [Abstract][Full Text] [Related]
17. [Interferon therapy of multiple sclerosis].
Jensen D
Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
[TBL] [Abstract][Full Text] [Related]
18. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
[TBL] [Abstract][Full Text] [Related]
19. Glatiramer acetate (Copaxone).
Francis DA
Int J Clin Pract; 2001; 55(6):394-8. PubMed ID: 11501229
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
Wiendl H; Hohlfeld R
Neurology; 2009 Mar; 72(11):1008-15. PubMed ID: 19289741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
